title: E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.
abstract: OBJECTIVE
  To compare the frequency and pattern of E-cadherin expression in endometrioid, papillary serous, and clear cell carcinomas of the endometrium.
  
  
  METHODS
  E-cadherin expression was examined in 76 endometrial carcinomas by immunohistochemistry using a monoclonal antibody to E-cadherin and was correlated with poor prognostic indicators such as depth of myometrial invasion, lymph node status, and intraperitoneal spread. The frequency of expression was compared between endometrioid, papillary serous, and clear cell carcinomas by the Fisher exact test. Logistic regression was used to examine the simultaneous effect of histological type and tumor grade on E-cadherin expression.
  
  
  RESULTS
  Sixty-three endometrioid, nine papillary serous, two clear cell, and two carcinomas of mixed histology were examined. E-cadherin negative tumors were more likely to be poorly differentiated (P <.01), have cervical extension (P =.02), have positive peritoneal cytology (P <.01), and have adnexal spread (P =.01) when compared with E-cadherin positive tumors. Papillary serous and clear cell carcinomas were significantly less likely to express E-cadherin than endometrioid carcinoma (38% versus 95%, P <.001). Tumor grade and histological type were identified as significant predictors of E-cadherin expression in univariable analysis; however, only histological type remained significant in multivariable analysis (P =.01). When grade was controlled, endometrioid carcinoma remained 23 times more likely to express E-cadherin than papillary serous and clear cell carcinomas.
  
  
  CONCLUSIONS
  Papillary serous and clear cell carcinomas are significantly less likely to express E-cadherin than endometrioid tumors. This difference may account for the more aggressive behavior of papillary serous and clear cell carcinomas.
authors.affiliation: Department of Obstetrics and Gynecology, St. Luke's-Roosevelt Hospital and Beth Israel Medical Center, New York, New York 10003, USA. kholcomb@chpnet.org
authors.forename: Kevin
authors.initials: K
authors.lastname: Holcomb
authors.forename: Roberto
authors.initials: R
authors.lastname: Delatorre
authors.forename: Bader
authors.initials: B
authors.lastname: Pedemonte
authors.forename: Carla
authors.initials: C
authors.lastname: McLeod
authors.forename: Lisa
authors.initials: L
authors.lastname: Anderson
authors.forename: Joseph
authors.initials: J
authors.lastname: Chambers
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000473:pathology* / Q000601:surgery; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001707:Biopsy, Needle; D015820:Cadherins / Q000032:analysis / Q000378:metabolism*; D015331:Cohort Studies; D016001:Confidence Intervals; D046508:Culture Techniques; D018283:Cystadenocarcinoma, Papillary / Q000473:pathology* / Q000601:surgery; D016889:Endometrial Neoplasms / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016015:Logistic Models; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D011336:Probability; D011379:Prognosis; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D015820:Cadherins